Atle Fund Management AB Grows Stake in Disc Medicine, Inc. $IRON

Atle Fund Management AB increased its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 85.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,690 shares of the company’s stock after buying an additional 21,038 shares during the period. Disc Medicine accounts for approximately 1.2% of Atle Fund Management AB’s portfolio, making the stock its 29th largest holding. Atle Fund Management AB’s holdings in Disc Medicine were worth $3,019,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. CWM LLC grew its position in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after buying an additional 711 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after acquiring an additional 181 shares during the last quarter. Avanza Fonder AB boosted its position in shares of Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after acquiring an additional 585 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Disc Medicine by 383.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after purchasing an additional 3,152 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

IRON has been the subject of several research analyst reports. Wedbush reiterated an “outperform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Truist Financial lifted their price objective on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Finally, TD Cowen restated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.45.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $77.32 on Friday. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The stock has a market cap of $2.92 billion, a PE ratio of -14.45 and a beta of 0.87. The company’s fifty day moving average is $83.23 and its 200 day moving average is $74.08. Disc Medicine, Inc. has a 52 week low of $30.82 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). Research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total value of $3,722,000.00. Following the completion of the sale, the chief executive officer owned 171,828 shares in the company, valued at approximately $15,988,595.40. The trade was a 18.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Rahul Khara sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $69.74, for a total transaction of $69,740.00. Following the completion of the transaction, the insider owned 37,793 shares in the company, valued at $2,635,683.82. This represents a 2.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 275,470 shares of company stock worth $24,966,170 over the last three months. Corporate insiders own 3.64% of the company’s stock.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.